KalVista Pharmaceuticals (KALV) Tops Q1 EPS by 3c

KalVista Pharmaceuticals (NASDAQ: KALV) reported Q1 EPS of ($0.87), $0.03 better than the analyst estimate of ($0.90).

For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.

You May Also Be Interested In

• Wolfe Research Upgrades Janux Therapeutics (JANX) to Outperform, 'An ARM Out of the Penalty Box'
• Morgan Stanley Starts Q32 Bio Inc. (QTTB) at Overweight
• Barclays Downgrades Merlin Properties SA (MRL:SM) (MRPRF) to Equalweight